ISDS Case Map
investor-state disputes | ISDS
The Ecuadorian government hailed a decision by an International Center for Settlement of Investment Disputes arbitration panel, which said it lacked jurisdiction over a lawsuit brought against Quito by US-based Murphy Oil Corporation.
With the upcoming meeting of the Committee on Internal Trade (CIT) ministers in Saskatoon on December 3, a wide cross-section of Canadian civil society groups are urging governments to deny corporations the right to sue the provinces and territories under the Agreement on Internal Trade (AIT) as requested by a coalition of business groups this week.
Over $326 million in compensation has already been paid out by governments to mainly US corporations in the 66 NAFTA cases filed to date.
Uruguay's Supreme Court on Friday dismissed a constitutional challenge brought by tobacco giant Philip Morris that disputes the tiny South American country's anti-tobacco laws.
On October 15 Georgian law enforcers detained Israeli businessmen offering Deputy Minister of Finance, Avtandil Kharadze USD 7 million for him to convince the Georgian Government not to challenge a decision of the International Centre for Settlement of Investment Disputes (ICSID).
The US government has called for the creation of a dispute settlement panel under the North American Free Trade Agreement to rule on Mexico’s decision to pursue a complaint about US labelling rules for ‘dolphin safe’ tuna at the WTO rather than under NAFTA.
Gold Reserve's claim alleges violations of three provisions of the Canada-Venezuela BIT culminating in the effective expropriation of Gold Reserve's investments in the Brisas gold/copper project and the Choco 5 gold property.
At an UNCTAD workshop held in Xiamen earlier this month, Korea introduced its model for preventing investor-state disputes through aftercare services.
Uruguayan officials announced plans Thursday to take further steps to toughen controls on tobacco despite a pending legal battle with global cigarette powerhouse Philip Morris International.
The Indian government’s doublespeak on generic medicines has the stakeholders in a tizzy.
